Free Trial
NASDAQ:HCWB

HCW Biologics Q2 2025 Earnings Report

HCW Biologics logo
$1.18 -0.27 (-18.62%)
Closing price 04:00 PM Eastern
Extended Trading
$1.18 +0.01 (+0.42%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCW Biologics EPS Results

Actual EPS
-$6.79
Consensus EPS
$1.80
Beat/Miss
Missed by -$8.59
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$7.00 million
Beat/Miss
Missed by -$6.99 million
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 18, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

HCW Biologics' Q2 2026 earnings is estimated for Friday, August 7, 2026, based on past reporting schedules

HCW Biologics Earnings Headlines

$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…tc pixel
HCW Biologics Raises $4M in Private Placement Financing
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

View HCW Biologics Profile